p300/CBP bromodomain inhibitor
PD observed in serial biopsies from Ph. I
50 mg QD, 3-d-on-4-off; origin not discussed
Cancer Discovery, Jan. 11, 2021
ICR / Royal Marsden / CellCentric, UK
CCS1477
1 min read
The CellCentric p300/CBP inhibitor, CCS1477, is an orally available drug in early development for advanced prostate cancer, and is structurally distinct from the p300/CBP inhibitor we covered in Apr. 2020. In agreement with its proposed MoA, it impacts AR and MYC signaling in serial tumor biopsies acquired from its first-in-human Ph. I trial. It will be interesting to see whether the agent is able to demonstrate a significant survival and quality-of-life benefit in late-stage disease given the likely on-target effects of p300/CBP inhibition on certain healthy cells.
Search By Structure
- Remogliflozin etabonate
- GLPG2451
- BI 730357
- MLi-2
- “compound 1”
- “compound 5i”
- E7386
- NVS-BET-1
- “compound 16”
- JNJ-63576253
- Dosimertinib
- BMS-986242
- CCS1477
- Con B-1
Molecules of the Month
2023
2022
2021
2020